

DREAMM 4: A Phase I/II single-arm open-label study to explore safety and clinical activity of belantamab mafodotin (GSK2857916) administered in combination with pembrolizumab in patients with relapsed/refractory multiple myeloma (RRMM)

Poster No: 1105TIP

Authors

Trudel S¹, Nooka AK², Fecteau D³, Talekar M³, Jewell RC⁴, Williams D³, Evans J⁵, and Opalinska J³

Affiliations

¹Princess Margaret Cancer Centre, Toronto, Canada, ON; ²Winship Cancer Institute, Emory University, Atlanta, GA, USA; ³GlaxoSmithKline, Collegeville, PA, USA; ⁴GlaxoSmithKline, Research Triangle Park, NC, USA; ⁵GlaxoSmithKline, Stockley Park, Middlesex, UK

Presenting author:

suzanne.trudel@uhn.on.ca

Background



BCMA is a cell-surface receptor highly expressed in MM and other B-cell malignancies^{1,2}

BCMA promotes the growth and survival of MM cells and is virtually absent on naive and memory B cells,^{1,3,4} making it an ideal therapeutic target in MM⁵⁻⁹



Belantamab mafodotin (GSK2857916) is a first-in-class, anti-BCMA immune-conjugate with an afucosylated, humanized anti-BCMA mAb conjugated by a protease-resistant cysteine linker to a microtubule disrupting agent, MMAF

Preclinical data indicate that belantamab mafodotin specifically binds to BCMA, eliminating myeloma cells by multimodal mechanisms, including delivery of MMAF to BCMA-expressing malignant plasma cells, enhancing antibody-dependent cellular cytotoxicity and leveraging immunogenic cell death^{2,10}

A favourable safety profile and clinical activity of belantamab mafodotin as a monotherapy has been shown in heavily pre-treated participants with MM, with deep and durable responses reported (NCT02064387): ORR was 60% with a mPFS of 12 months (95% CI: 3.1–not estimable).¹¹ Of those participants without prior daratumumab treatment an ORR of 71.4% (95% CI: 47.8–88.7) was achieved; whereas in participants with prior daratumumab treatment and refractory to both immunomodulators and proteasome inhibitors an ORR of 38.5% (95% CI: 13.9–68.4) was achieved

PD-L1 overexpression may be a mechanism of immune evasion in MM¹²

Pembrolizumab, a selective, humanised IgG4 anti-PD-1 monoclonal antibody that blocks the interaction of PD-1 with PD-L1 and PD-L2, may synergise with immunomodulatory drugs to enhance tumour suppression



We hypothesised that T cell-dependent anti-tumour response induced by belantamab mafodotin may be augmented by combining with pembrolizumab



Trial objectives

To evaluate safety and determine the RP2D and preliminary clinical activity of belantamab mafodotin in combination with pembrolizumab in participants with RRMM previously treated with ≥3 prior lines

Trial design: DREAMM 4 (NCT03848845)



1 Part 1: Dose escalation N≤12


Key inclusion criteria:

- ≥18 years of age
- ECOG PS 0–1
- 3 or more prior lines of anti-myeloma therapies including an IMiD, proteasome inhibitor, and anti-CD38 antibody
- Measurable disease

Prior anti-BCMA treatments, including belantamab mafodotin, are not excluded

Key exclusion criteria:

- Any prior anti-MM therapy or investigational drug within 14 days
- Prior treatment with a monoclonal antibody within 30 days
- Prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent, or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (e.g. CTLA-4, OX40, CD137) and was discontinued from that treatment due to a Grade 3 or higher irAE
- Corneal epithelial disease except mild punctate keratopathy
- Major surgery within the last 4 weeks
- Active renal condition, liver or biliary disease, or infection
- Active CNS metastases and/or carcinomatous meningitis
- Autoimmune disease that has required systemic treatment in the past 2 years
- Diagnosed immunodeficiency or any form of immunosuppressive therapy within 7 days
- Prior allogenic tissue/solid organ transplant



OBJECTIVE

- Determine safety, tolerability, and establish the RP2D of the combination of belantamab mafodotin and pembrolizumab

1 PRIMARY ENDPOINT

- Percentage of participants with AE/DLT

2 SECONDARY ENDPOINTS

- ORR
- PK/ADA profiles

During the dose escalation, at least 3 evaluable participants will be tested per dose level. mTPI¹³ design will guide dose escalation and RP2D of belantamab mafodotin

Safety data will be examined on an ongoing basis to support dose-escalation decisions


Safety monitoring



An independent safety review committee will review safety data

An additional stopping rule for Part 2 may stop enrolment early if (starting from 5 participants dosed) the observed rate of treatment-related ≥Grade 4 AEs equal or exceeds the specified rate (12%) at one-sided alpha level of 0.025 based on the 11% Grade 4 or higher AEs observed in the monotherapy study (NCT02064387)

2 Part 2: Dose expansion N≤28



OBJECTIVE

- Evaluate clinical activity, confirm safety and collect PK information for belantamab mafodotin, administered in combination with pembrolizumab dosing schedules identified in Part 1

1 PRIMARY ENDPOINT

- ORR

2 SECONDARY ENDPOINTS

- Ocular findings on ophthalmic exam
- Percentage of participants with AE
- Clinical benefit rate
- Duration of response
- Progression-free survival
- Time to disease progression
- OS
- PK/ADA profile

EXPLORATORY ENDPOINTS

- MRD in participants who achieve ≥VGPR
- BCMA expression and clinical response
- Genetic variations and clinical response
- Treatment and disease-related PROs
- Health-related quality of life

Participants will be treated until disease progression, intolerable toxicity, informed consent withdrawal, or for a maximum of 35 cycles (approximately 2 years)

Disease progression is assessed according to IMWG 2016 response criteria¹⁴

Current status



Presented at

The European Society for Medical Oncology (ESMO) Congress, Barcelona, 27 September – 1 October 2019.

Abbreviations

ADA, anti-drug antibodies; AE, adverse event; BCMA, B-cell maturation antigen; CD, cluster of differentiation; CI, confidence interval; CNS, central nervous system; CTLA, cytotoxic T-lymphocyte-associated protein; DLT, dose-limiting toxicities; ECOG, Eastern Cooperative Oncology Group; Ig, immunoglobulin; IMiD, immunomodulatory imide drugs; IMWG, International Myeloma Working Group; irAE, immune-related adverse event; MM, multiple myeloma; MMAF, microtubule inhibitor monomethyl auristatin F; mPFS, median progression-free survival; MRD, minimal residual disease; mTPI, modified toxicity probability interval; ORR, overall response rate; OS, overall survival; PD-1, programmed cell death protein 1; PD-L, programmed cell death ligand; PK, pharmacokinetics; PR, partial response; PRO, patient-reported outcome; RP2D, recommended Phase II dose; RRMM, relapsed/refractory multiple myeloma; VGPR, very good partial response

Disclosures

ST: advisory or consulting role, research funding, and honoraria: GSK; AKN: advisory or consulting role: Adaptive, Amgen, Bristol-Myers Squibb, Celgene, GSK, Janssen, Spectrum, Takeda; research funding: Bristol-Myers Squibb, Celgene, Janssen, Takeda; research funding (institution): Astora, Amgen, Bristol-Myers Squibb, Celgene, Genentech, GSK, Janssen, KITE pharmaceuticals, Roche, Spectrum, Takeda; honoraria: Adaptive, Amgen, Bristol-Myers Squibb, Celgene, GSK, Janssen, Spectrum, Takeda; DF, MT, RCJ, JE and JO are employees of and stockholders in GSK. DW is an employee of GSK.

Acknowledgements

Editorial assistance was provided by Aaron Borg, PhD and Fiona Woodward, PhD, of Fishawack India Ltd, UK, and funded by GlaxoSmithKline. Funding for this study 204591, NCT0223955, was provided by GSK in collaboration with Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA; drug linker technology is licensed from Seattle Genetics; monoclonal antibody is produced using POTELLIGENT Technology licensed from BiWi, pembrolizumab was supplied by Merck

References

- Tal Y, et al. *Blood*. 2014; 123: 3128–3138
- Tal Y, Anderson KC. *Immunotherapy*. 2015; 7: 1187–1189
- O'Connor BP, et al. *J Exp Med*. 2004; 199: 91–97
- Chiu A, et al. *Blood*. 2007; 109: 729–739
- Malankody S, et al. *Blood*. 2018; 132: 957–957
- Raja NS, et al. *J Clin Oncol*. 2018; 36: 8007–8007
- Shah N, et al. *Blood*. 2016; 128: 488–488
- Topp MS, et al. *Blood*. 2018; 132: 1010–1010
- Zhao WH, et al. *J Hemato Oncol*. 2018; 11: 141
- Montes De Oca R, et al. *EHA*. 2019; 266357: PFF558
- Trudel S, et al. *Blood Cancer J*. 2019; 9: 39
- McLaughlin J, et al. *JAMA Oncol*. 2016; 2: 45–65
- Ji Y, et al. *Clin Trials*. 2010; 7: 653–663
- Kumar S, et al. *Lancet Oncol*. 2016; 17: e328–e346

Please find the online version of this poster by scanning the QR code or via http://ago.ca_ESMO19

Copies of this poster obtained through QR (Quick Response) and/or text key codes are for personal use only and may not be reproduced without written permission of the authors.

